• menu
    Market Place Market Place
    Sourcing Support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.
    |
    Weekly News Recap #Phispers
    FDA okays GSK’s Exdensur as first biologic, add-on med for severe asthma; issues OAI status to Sun Pharma’s India facility

    FDA okays GSK’s Exdensur as first biologic, add-on med for severe asthma; issues OAI status to Sun Pharma’s India facility

    As the year draws to a close, the US Food and Drug Administration (FDA) appears busy approving drugs at a fast pace. This week...

    Impressions : 435

    Lilly to invest US$ 6 bn in new API plant in Alabama; Biocon buys remaining stake in Biocon Biologics, makes it 100% subsidiary

    Lilly to invest US$ 6 bn in new API plant in Alabama; Biocon buys remaining stake in Biocon Biologics, makes it 100% subsidiary

    In this week’s Phispers, Eli Lilly announced yet another investment in the US — this time to build its largest API ...

    Impressions : 730

    Lilly cuts price of Zepbound; leaked memo on child deaths due to Covid vaccines triggers reaction from former FDA chiefs

    Lilly cuts price of Zepbound; leaked memo on child deaths due to Covid vaccines triggers reaction from former FDA chiefs

    In Phispers this week, Eli Lilly reduced prices of its obesity drug Zepbound sold through LillyDirect, aiming to expand access...

    Impressions : 953

    Lilly becomes first pharma to hit US$ 1 tn valuation; FDA clears Padcev-Keytruda combo for bladder cancer

    Lilly becomes first pharma to hit US$ 1 tn valuation; FDA clears Padcev-Keytruda combo for bladder cancer

    In Phispers this week, Eli Lilly became the first pharmaceutical company to reach a market valuation of US$ 1 trillion, driven ...

    Impressions : 1370

    Merck to buy Cidara for US$ 9.2 bn to strengthen infectious disease portfolio; J&J to acquire Halda for US$ 3.05 bn

    Merck to buy Cidara for US$ 9.2 bn to strengthen infectious disease portfolio; J&J to acquire Halda for US$ 3.05 bn

    In this week’s Phispers, Merck struck a US$ 9.2 billion deal to acquire Cidara Therapeutics to strengthen its infectious-...

    Impressions : 759

    Pfizer seals up to US$ 10 bn deal for Metsera; FDA lifts black box warning on hormone therapies for menopause

    Pfizer seals up to US$ 10 bn deal for Metsera; FDA lifts black box warning on hormone therapies for menopause

    In Phispers this week, Pfizer won its high stakes battle with Novo Nordisk for the obesity-focused biotech Metsera. The deal i...

    Impressions : 1060

    Pfizer, Novo escalate bidding war for obesity-drug developer Metsera; Kimberly-Clark to buy Kenvue for US$ 48.7 bn

    Pfizer, Novo escalate bidding war for obesity-drug developer Metsera; Kimberly-Clark to buy Kenvue for US$ 48.7 bn

    As we return from our one-week break due to the CPhI Worldwide, we find our double-dose Phispers edition to be filled with se...

    Impressions : 1026

    Innovent, Takeda ink up to US$ 11.4 bn oncology deal; FDA clears Novo’s Rybelsus to reduce heart risk in diabetics

    Innovent, Takeda ink up to US$ 11.4 bn oncology deal; FDA clears Novo’s Rybelsus to reduce heart risk in diabetics

    In this week’s Phispers, China’s Innovent Biologics signed one of the largest cross-border biotech deals in Asia. U...

    Impressions : 1162

    Novo targets MASH with up to US$ 5.2bn Akero buy; BMS acquires cell therapy developer Orbital for US$ 1.5 bn

    Novo targets MASH with up to US$ 5.2bn Akero buy; BMS acquires cell therapy developer Orbital for US$ 1.5 bn

    In this week’s Phispers, Novo Nordisk and Bristol Myers Squibb (BMS) struck multi-billion-dollar acquisitions to expand t...

    Impressions : 818

    Chiesi, Arbor in US$ 2 bn gene therapy deal; Lilly to invest over US$ 1 bn in India; FDA okays Boehringer’s rare lung disease drug

    Chiesi, Arbor in US$ 2 bn gene therapy deal; Lilly to invest over US$ 1 bn in India; FDA okays Boehringer’s rare lung disease drug

    In news this week, Italy’s Chiesi Group announced a deal worth up to US$ 2 billion with US-based Arbor Biotechnologies to...

    Impressions : 3501

    Trump, Pfizer seal deal to offer drug discounts; FDA approves Eli Lilly’s oral breast cancer pill

    Trump, Pfizer seal deal to offer drug discounts; FDA approves Eli Lilly’s oral breast cancer pill

    This week, US President Donald Trump announced a deal with Pfizer to sell medicines through a new federal website, TrumpRx.go...

    Impressions : 857

    Pfizer buys Metsera for up to US$ 7.3 bn, Roche acquires 89bio; FDA okays injectable version of Merck’s Keytruda

    Pfizer buys Metsera for up to US$ 7.3 bn, Roche acquires 89bio; FDA okays injectable version of Merck’s Keytruda

    In this week’s Phispers, Pfizer announced the acquisition of New York-based biotech Metsera for up to US$ 7.3 billion, ma...

    Impressions : 1508

    Novartis inks US$ 5.7 bn licensing deal with Monte Rosa for immune-related diseases; GSK, Lilly pledge more investments in US

    Novartis inks US$ 5.7 bn licensing deal with Monte Rosa for immune-related diseases; GSK, Lilly pledge more investments in US

    In this week’s news, drugmakers continued to invest heavily in the US in order to avoid tariffs. GSK said it will invest ...

    Impressions : 1084

    Advent to sell generic unit to PE firm GTCR for US$ 4.8 billion; Novo shapes up for obesity race by cutting 9,000 jobs

    Advent to sell generic unit to PE firm GTCR for US$ 4.8 billion; Novo shapes up for obesity race by cutting 9,000 jobs

    In this week’s news, Advent International has agreed to sell the Czech generic drugmaker Zentiva to private equity firm G...

    Impressions : 848

    Novartis inks US$ 5.2 bn cardiology deal with China’s Argo, US$ 2 bn deal with Arrowhead; FDA okays first GLP-1 generic for weight

    Novartis inks US$ 5.2 bn cardiology deal with China’s Argo, US$ 2 bn deal with Arrowhead; FDA okays first GLP-1 generic for weight

    Novartis signed two deals this week — a US$ 5.2 billion cardiology deal with China’s Argo Biopharmaceuticals, and a...

    Impressions : 913

    White House sacks CDC director; FDA okays Ionis’ Dawnzera, first RNA-based preventive for hereditary angioedema

    White House sacks CDC director; FDA okays Ionis’ Dawnzera, first RNA-based preventive for hereditary angioedema

    The Trump administration has fired US Centers for Disease Control and Prevention (CDC) Director Susan Monarez, post a policy di...

    Impressions : 1173

    FDA grants accelerated approval to Wegovy for treating MASH; Lilly, Superluminal ink US$1.3 bn AI deal to treat obesity

    FDA grants accelerated approval to Wegovy for treating MASH; Lilly, Superluminal ink US$1.3 bn AI deal to treat obesity

    This week’s Phispers brings you updates on key drug approvals. The US Food and Drug Administration (FDA) has granted acce...

    Impressions : 1573

    FDA grants accelerated nod to Boehringer’s lung cancer med; reinstates ousted CBER chief Vinay Prasad

    FDA grants accelerated nod to Boehringer’s lung cancer med; reinstates ousted CBER chief Vinay Prasad

    The US Food and Drug Administration (FDA) has granted an accelerated approval to Boehringer Ingelheim’s Hernexeos (zonger...

    Impressions : 1572

    Trump says pharma tariffs may touch 250% in 18 months; FDA okays Jazz Pharma’s rare brain tumor drug

    Trump says pharma tariffs may touch 250% in 18 months; FDA okays Jazz Pharma’s rare brain tumor drug

    The US Food and Drug Administration (FDA) has granted an accelerated approval to Jazz Pharmaceuticals’ Modeyso, a drug th...

    Impressions : 940

    Consortium makes ~US$ 3 bn offer to buy Bavarian Nordic; FDA approves PTC’s rare genetic disorder drug

    Consortium makes ~US$ 3 bn offer to buy Bavarian Nordic; FDA approves PTC’s rare genetic disorder drug

    The US Food and Drug Administration (FDA) has approved PTC Therapeutics’ oral drug to treat a rare genetic disorder known...

    Impressions : 998

    Astra to invest US$ 50 bn in US to avoid tariffs; Dr. Reddy’s to launch generic Wegovy in 87 countries next year

    Astra to invest US$ 50 bn in US to avoid tariffs; Dr. Reddy’s to launch generic Wegovy in 87 countries next year

    AstraZeneca and Biogen are the latest drugmakers to announce investments in the US to avoid import tariffs. AstraZeneca is in...

    Impressions : 1279

    Sarepta lays off 500 employees post second death in Elevidys trial; FDA chief proposes lowering PDUFA fee

    Sarepta lays off 500 employees post second death in Elevidys trial; FDA chief proposes lowering PDUFA fee

    This week’s Phispers brings you updates on cell and gene therapies (CGTs). After the death of a second teenaged boy last ...

    Impressions : 4329

    Merck buys Verona for US$ 10 bn, gains its COPD med; Summit, Astra reportedly in talks for US$ 15 bn cancer drug deal

    Merck buys Verona for US$ 10 bn, gains its COPD med; Summit, Astra reportedly in talks for US$ 15 bn cancer drug deal

    The world of pharmaceuticals continued to witness large deals. Merck announced a US$ 10 billion acquisition of Verona Pharma, g...

    Impressions : 804

    AbbVie doubles down on immunology with US$ 2.1 bn Capstan buyout; India’s Torrent buys controlling stake in JB Chem

    AbbVie doubles down on immunology with US$ 2.1 bn Capstan buyout; India’s Torrent buys controlling stake in JB Chem

    This week in Phispers, AbbVie struck a deal worth up to US$ 2.1 billion to acquire Capstan Therapeutics and its innovative in v...

    Impressions : 756

    Royalty Pharma inks US$ 2 bn cancer drug deal with Revolution; Astra-Daiichi’s Datroway wins US approval for lung cancer

    Royalty Pharma inks US$ 2 bn cancer drug deal with Revolution; Astra-Daiichi’s Datroway wins US approval for lung cancer

    In news this week, Royalty Pharma committed up to US$ 2 billion to Revolution Medicines for their promising pancreatic and lung...

    Impressions : 3090

    Lilly acquires gene-editing firm Verve for US$ 1.3 bn, BioNTech buys CureVac; Astra signs US$ 5.3 bn AI deal with China’s CSPC

    Lilly acquires gene-editing firm Verve for US$ 1.3 bn, BioNTech buys CureVac; Astra signs US$ 5.3 bn AI deal with China’s CSPC

    This week’s Phispers comes with news on several M&A deals. Eli Lilly made headlines with its US$ 1.3 billion acquisition ...

    Impressions : 741

    RFK Jr fires all 17 members of CDC’s vaccine committee; Merck’s oral cholesterol drug meets goals in late-stage trials

    RFK Jr fires all 17 members of CDC’s vaccine committee; Merck’s oral cholesterol drug meets goals in late-stage trials

    This week, US Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. dismissed all 17 members of the US Centers for D...

    Impressions : 1197

    BMS partners BioNTech in US$ 11 bn cancer drug deal; Sanofi to acquire Blueprint Medicines for US$ 9.5 bn

    BMS partners BioNTech in US$ 11 bn cancer drug deal; Sanofi to acquire Blueprint Medicines for US$ 9.5 bn

    The pharmaceutical sector saw several significant deals with major players expanding their portfolios. Bristol Myers Squibb (BM...

    Impressions : 704

    Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.